Pre-clinically, this combination is particularly efficacious against CT26 colon carcinoma cells (108–110), which interestingly harbor a Cdkn2a deletion and expresses functional RB (143, 144), likely rendering it highly sensitive to the tumor-intrinsic immunomodulatory effects of CDK4/6 inhibition. The gene discussed is CDK4; the disease is colon carcinoma.